AstraZeneca, Johnson & Johnson resume U.S. tests of COVID-19 vaccines
Two drugmakers say they have the go-ahead to resuming U.S. testing of their COVID-19 vaccine candidates. Both are in the final stage of testing before the companies can seek regulatory approval.
As threat of valley fever grows beyond the Southwest, push is on for vaccine
Valley fever is diagnosed in the range of 10,000 to 15,000 cases a year in the U.S. with 160 fatalities, though both numbers are likely several times higher in reality because many cases are never identified.
Additional Support Provided By:
